Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STX-721/PFL-721 study in mutation-selected non-small cell lung cancer
2023-506759-51-00Phase 2Authorised
- Sponsor
- Pierre Fabre Laboratories
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2 trial of PFL-721 in non-small cell lung cancer (NSCLC), sponsored by Pierre Fabre Laboratories. Planned start Mar 2024; status: authorised.
02
Drugs
PFL-721
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-506759-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506759-51-00.